Synaptophysin expression on circulating tumor cells (CTCs) in patients with castration resistant prostate cancer (CRPC) undergoing treatment with abiraterone acetate or enzalutamide

BACKGROUND: With the advent of secondary androgen receptor (AR)-targeted therapies in metastatic castration resistant prostate cancer (CRPC), non-adenocarcinoma prostate cancers are becoming more prevalent. Many of these cancers express neuroendocrine markers, which may provide biomarkers for emerge...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Urol Oncol
Main Authors: Pal, Sumanta Kumar, He, Miaoling, Chen, Lin, Yang, Lixin, Pillai, Raju, Twardowski, Przemyslaw, Hsu, JoAnn, Kortylewski, Marcin, Jones, Jeremy O.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5899661/
https://ncbi.nlm.nih.gov/pubmed/29289429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.12.006
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares